Harbor Capital Advisors Inc. Has $3.05 Million Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Harbor Capital Advisors Inc. boosted its position in Vaxcyte, Inc. (NASDAQ:PCVX) by 392.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 40,342 shares of the company’s stock after buying an additional 32,149 shares during the period. Harbor Capital Advisors Inc.’s holdings in Vaxcyte were worth $3,046,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. Darwin Global Management Ltd. lifted its stake in shares of Vaxcyte by 374.3% in the 1st quarter. Darwin Global Management Ltd. now owns 2,750,804 shares of the company’s stock valued at $187,907,000 after purchasing an additional 2,170,845 shares during the period. Vanguard Group Inc. lifted its stake in Vaxcyte by 15.2% in the first quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock valued at $665,152,000 after buying an additional 1,284,883 shares during the period. Norges Bank bought a new position in shares of Vaxcyte during the 4th quarter worth approximately $57,494,000. Capital Research Global Investors grew its position in shares of Vaxcyte by 20.4% during the 1st quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock worth $282,839,000 after buying an additional 700,414 shares during the period. Finally, Janus Henderson Group PLC increased its stake in shares of Vaxcyte by 9.9% in the 1st quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock valued at $524,117,000 after acquiring an additional 692,492 shares in the last quarter. Institutional investors own 96.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research note on Thursday, June 20th. Needham & Company LLC reissued a “buy” rating and set a $95.00 price objective on shares of Vaxcyte in a research report on Wednesday.

Vaxcyte Stock Down 2.1 %

PCVX stock traded down $1.57 during midday trading on Wednesday, reaching $72.36. 266,373 shares of the company’s stock traded hands, compared to its average volume of 785,500. The firm’s fifty day moving average price is $76.80 and its 200-day moving average price is $71.55. Vaxcyte, Inc. has a 52 week low of $44.20 and a 52 week high of $87.71. The company has a market cap of $7.87 billion, a price-to-earnings ratio of -17.27 and a beta of 0.97.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Wednesday, May 8th. The company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.28. Analysts forecast that Vaxcyte, Inc. will post -3.93 earnings per share for the current year.

Insiders Place Their Bets

In other news, SVP Mikhail Eydelman sold 1,667 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $72.06, for a total value of $120,124.02. Following the completion of the sale, the senior vice president now owns 31,161 shares in the company, valued at approximately $2,245,461.66. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Vaxcyte news, SVP Elvia Cowan sold 5,000 shares of the business’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $85.00, for a total value of $425,000.00. Following the transaction, the senior vice president now owns 12,723 shares of the company’s stock, valued at $1,081,455. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Mikhail Eydelman sold 1,667 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $72.06, for a total value of $120,124.02. Following the completion of the transaction, the senior vice president now owns 31,161 shares of the company’s stock, valued at approximately $2,245,461.66. The disclosure for this sale can be found here. In the last ninety days, insiders sold 103,766 shares of company stock valued at $7,923,441. Corporate insiders own 3.10% of the company’s stock.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.